Kornimate/medical-research-clean huggingface dataset:
canadian cp registry - registre canadien de la paralysie cérébrale

Conditions: Cerebral Palsy

Summary: the canadian cerebral palsy (cp) registry is a confidential, nation-wide collection of medical and social information about children with cerebral palsy. the registry was first implemented in 2003 in 6 administrative regions of quebec and was later extended to paediatric centres in newfoundland, nova scotia, ontario, alberta, and british columbia. over 1850 children living with cerebral palsy have been registered so far. the registry is the first national registry for cerebral palsy in north america.

the canadian cerebral palsy registry is a multi-regional canadian registry to identify potential risk factors related to pregnancy and interactions of the environment and genetics. the registry provides researchers with the approximate number of children with cerebral palsy across canada, and data in the registry helps researchers explore reasons behind the causes of cerebral palsy, in addition to supporting studies which may lead to improvements in the overall care of children with cp. cerebral palsy is the most common cause of physical disability in children in canada and it is important that we gain a better understanding of its prevalence, risk factors and current clinical profile. the canadian cp registry provides valuable data from different canadian regions which can be shared and analyzed so as to provide answers to these important questions. specifically, the registry serves to: * characterize the profile of children living with cp across the country * identify risk factors associated with cp * monitor the prevalence of cp across the country * provide a platform for subject recruitment for population-based research on cp

Eligibility criteria:
inclusion criteria: * under 18 (age cut-off varies by region) * diagnosed with cerebral palsy * living in canada exclusion criteria: * uncertain cp diagnosis

Keywords: cerebral palsy canada registry
rescue extracranial vertebral stenting in tandem occlusions

Conditions: Acute Stroke; Ischemic Stroke, Acute; Vertebro Basilar Ischemia

Summary: the acute vertebrobasilar occlusion associated with the poor prognosis, particularly tandem occlusion. however, few data on the efficacy of the endovascular therapy was indicated in this occlusion. the investigators reported whether the additional rescue extracranial stenting improved clinical outcome by modified rankin scale (mrs) score within 3 months after the procedure

acute vertebrobasilar artery occlusion is one of the cerebrovascular diseases with high disability and mortality rates. although mechanical thrombectomy has recently been demonstrated an effective treatment for large vessel occlusions of posterior circulation, the treatment strategies depending on the specific pathophysiology. tandem occlusion in posterior circulation is less frequently than in anterior one, comprises severe stenosis or occlusion of the extracranial vertebral artery ipsilateral to its intracranial and basilar occlusion. the recent studies showed the benefit of the "distal-to-proximal" approach, there were many tecniques to achieved the successful recanalization. besides, the use of dotter technique allowed 8f guiding catheter to cross the extracranial lesions easily and save the procedural time. however, the diagnosis 5f-dotter, like the dilator-dotter, has not been mentioned in previous studies. therefore, the aim of the our study was to assess the improvement of outcomes at 3 months posttreatment in patients receiving rescue extracranial vertebral stenting

Eligibility criteria:
inclusion criteria: * age \> 18 years old * onset to treatment time \< 24 hours * nihss \> 5 * pc-aspects ≥ 5 exclusion criteria: * premorbid mrs \> 2 * extensive, bilateral brain-stem infarction on neuroimaging * cerebellar mass effect on neuroimaging * loss to follow-up

Keywords: tandem occlusions posterior circulation rescue extracrnial stenting
online noninvasive assessment of human brain death and deep coma by near-infrared spectroscopy

Conditions: Brain Death; Coma

Summary: this study aims to assess brain death and deep coma with the self-made near infrared spectroscopy (nirs) instrument. the investigators used the noninvasive method to monitor the δ\[hbo2\] (the concentration changes in oxy-hemoglobin) and δ\[hb\] (the concentration changes in deoxy-hemoglobin) in the region around the forehead of medically evaluated participating patients and healthy subjects. a multiple-phase protocol at varied fraction of inspired o2 were utilized during the assessment.

brain death is an irreversible loss of all brain functions, while deep coma is a profound state of unconsciousness associated with depressed cerebral activity. timely distinguishing the two states is crucial for saving patients. the noninvasive, sensitive, universally available, and timely ancillary method to assess brain death and deep coma has not been established. this study aims to explore a noninvasive and straightforward way in brain death and deep coma online assessment. the changes of hemodynamic parameters including oxyhemoglobin (hbo2) and deoxyhemoglobin (hb) were detected by near infrared spectroscopy instrument attached on the forehead of participators. a multiple-phase protocol at varied fraction of inspired o2(fio2) were utilized during the assessment. then the investigators compared the multiple physiological parameters changes among different groups at different fio2.

Eligibility criteria:
inclusion criteria: * patients who have had brain death or serious brain trauma. * patients who have deep coma with autonomous respiration according to gcs coma scale * healthy people who are interested in optical assessment of hemodynamic parameters exclusion criteria: * patients who are in pregnancy or have plan to conception. * patients who have vertebra surgery or have plan of surgery. * patients who are inappropriate to join this trial judged by the radiologists or specialists. * aids, active hepatitis, tuberculosis, syphilis * patients who regularly take anticoagulants, antiplatelet drugs

Keywords: brain death deep coma oxygen metabolism near infrared spectroscopy
effect of vitamin d oral supplements on 25 oh vitamin d levels

Conditions: Vitamin D Deficiency

Summary: vitamin d deficiency is common world wide. 25 oh vitamin d level is the best indicator of vitamin d status. vitamin d supplements are available as vitamin d2 or d3, in small daily or large weekly/monthly doses. controversy continues on the relative potency of vitamin d2 compared to d3 and of daily compared to weekly or monthly doses, in increasing/maintaining total 25 oh vitamin d level. the investigators plan to conduct a controlled trial to compare the effect of various vitamin d supplements on 25 oh vitamin d levels in healthy adults with starting 25 oh vitamin d level between 20 to 50 nmol/l.


Eligibility criteria:
inclusion criteria: * healthy adults living in riyadh area who consume no more than one serving of milk/day, do not take vitamin supplement, habitually have less than 10 hr of sun exposure per week, don't suffer from granulomatous conditions, liver disease, or kidney disease, and don't take anticonvulsants, barbiturates, or steroids. * 25 oh vitamin d level between 20 to 50 nmol/l.

Keywords: vitamin d2, vitamin d3, 25 oh vitamin d2, 25 oh vitamin d3
bioequivalence study of sitagliptin/metformin combination tablet (mk0431a-122)

Conditions: Type 2 Diabetes

Summary: this study will test the hypothesis that the final market image (fmi) sitagliptin/metformin 50 mg/500 mg and 50 mg/850 mg (fixed dose combination) fdc tablet and co-administration of corresponding doses of sitagliptin and china-sourced metformin as individual tablets will be bioequivalent based on assessment of the auc(0-t) and cmax, for both sitagliptin and metformin.


Eligibility criteria:
inclusion criteria: * subject is of chinese descent * subject is in good health * subject is a non-smoker exclusion criteria: * subject has a history of stroke or chronic seizures * subject has a history of cancer * subject has had major surgery, donated blood or participated in another investigational study within the past 4 weeks

Keywords: type 2 diabetes
electronic early notification of sepsis in hospitalized ward patients

Conditions: Sepsis

Summary: screening for sepsis has been recommended by the surviving sepsis campaign clinical practice guidelines to facilitate early identification and early management of sepsis. however, the optimal tool remains unknown.the objective of this trial is to examine the effect of an electronic sepsis alert tool on reducing hospital mortailty in patients admitted to medical-surgical-oncology wards.

the study aims to examine the effect of screening for sepsis using an electronic sepsis alert versus no alert in hospitalized patients admitted to wards using an active sepsis alert system compared with wards with no active (masked) sepsis alert system on hospital mortality by day 90. the wards will be randomized in a stepped-wedge cluster fashion.

Eligibility criteria:
ward level inclusion and exclusion criteria inclusion criteria: 1. inpatient wards, defined as wards used to manage inpatients, in the five ministry of national guard health affairs (mngha) hospitals, kingdom of saudi arabia exclusion criteria: 1. cardiology, transplant, pediatric, obstetric wards 2. intensive care units and emergency department 3. operating rooms 4. outpatients 5. day care wards, endoscopy, outpatient procedure areas, hemodialysis units. patient level inclusion and exclusion criteria inclusion criteria: 1. aged 14 years or older 2. checked in as inpatient status to one of the study ward exclusion criteria: 1. no commitment for full life support on the time of arrival to the study ward

Keywords: sepsis ward patients screening qsofa
treatment shortening of mdr-tb using existing and new drugs

Conditions: Tuberculosis, Multidrug-Resistant

Summary: the purpose of this study is to compare the efficacy of a 'new treatment regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for nine or twelve months (investigational arm)' and 'the standard treatment regimen including injectables for 20 to 24 months (control arm)' for treating fluoroquinolone-sensitive multidrug-resistant tuberculosis.

this study is a phase ii/iii, multicenter, randomized, open-label clinical trial of non-inferiority design comparing a new regimen to the world health organization-endorsed conventional regimen for fluoroquinolone-sensitive mdr-tb. the control arm uses a conventional treatment regimen with second-line drugs including injectables for 20-24 months. the investigational arm uses a new shorter regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for 9 or 12 months depending on time to sputum culture conversion. the primary outcome is the treatment success rate at 24 months after treatment initiation. secondary outcomes include time to sputum culture conversion on liquid and solid media, proportions of sputum culture conversion on liquid media after 2 and 6 months of treatment, treatment success rate according to pyrazinamide resistance, and occurrence of adverse events grade 3 and above as evaluated by the common terminology criteria for adverse events. the population number is calculated as 102 per group (204 in total).

Eligibility criteria:
inclusion criteria: * males and females aged from 19 to 85 years * confirmed mdr-tb or rr-tb * on current tb therapy for ≤14 days at the time of enrollment. exclusion criteria: * known any quinolone-resistant mdr-tb * known xdr-tb * who are pregnant or who are unwilling to use proper contraceptives at childbearing age * medical history of galactose intolerance, lapp lactase deficiency, glucose-galactose malabsorption * the need for ongoing use of prohibited drugs while on study drugs * history of optic neuropathy or peripheral neuropathy * with any of the following test results: i.absolute neutrophil count \ 2.0 mg/dl, v.aspartate aminotransferase (ast or sgot) \>100 iu/l, vi.alanine aminotransferase (alt or sgpt) \>100 iu/l, vii.total bilirubin \> 2.0 mg/dl, viii.albumin \ 500ms * history of hypersensitivity reaction to the study drugs

Keywords: multidrug-resistant tuberculosis linezolid delamanid multicenter randomized trial non-inferiority shorter regimen
effect of transcutaneous electrical nerve stimulation in diabetic neuropathy

Conditions: Diabetic Neuropathy Peripheral

Summary: double-blind, randomized, placebo-controlled, clinical trial. patients with diabetic neuropathy will be randomly assigned to treatment with either tens or tens sham three times a week during 90 days. clinical determinations are: pain, levesls of tnf-alpha, il-6 and rpc-us


Eligibility criteria:
inclusion criteria: * diagnostic of type 2 diabetes \> 10 years * diagnostic of peripheral diabetic neuropathy less than 5 years * hba1c \> 6.5 and \< 9% * plasmatic glucose \>140 mg/dl and lees than 350 mg/dl * informed consent signed exclusion criteria: * use of implanted pacemaker or heart defibrillator * implanted brain stimulator * history of alcohol abuse * use of nsaid, stereoids * subjects with wounds, ulcers in legs * subjects with hepatic, renal o neurologic diseases

Keywords: diabetic neuropathy peripheral diabetic complications tens neuropathic treatments
percutaneous treatment of long native coronary lesions with drug-eluting stent-iv: (long-des-iv)

Conditions: Coronary Artery Disease

Summary: this randomized study is a multi-center, randomized, study to compare the efficacy of sirolimus (cypher) versus zotarolimus-eluting stent (endeavor resolute) implantation for long coronary lesions.

following angiography, patients with significant diameter stenosis \>50% and lesion length (\> 25mm) requiring single or multiple long-stent placement (total stent length\>28mm) by visual estimation and eligible for long-des iv trial inclusion and exclusion criteria will be randomized 1:1 to a) cypher and b) endeavor resolute stent by the stratified randomization method.

Eligibility criteria:
inclusion criteria: * the patient must be at least 18 years of age. * significant native coronary artery stenosis (\>50% by visual estimate) with lesion length of more than 25mm, which requiring single or multiple long stent placement (\>=28mm) * patients with silent ischemia, stable or unstable angina pectoris, ad non-st-elevation myocardial infarction * the patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethical committee of the respective clinical site. exclusion criteria: * any contraindication to any of the following medications: aspirin, heparin, clopidogrel, stainless steel, contrast agents, sirolimus, or everolimus. * an elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment. * acute st-segment-elevation mi or cardiogenic shock * terminal illness with life expectancy \<1 year * patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. * in-stent restenosis at target vessel (either bare metal stent or drug-eluting stent segment, non-target vessel isr is permitted) * patients with ef\<30%. * serum creatinine level \>=3.0mg/dl or dependence on dialysis. * patients with left main stem stenosis (\>50% by visual estimate).

Keywords: coronary artery disease stent
the use of ketamine as an anaesthetic during electroconvulsive therapy

Conditions: Depression

Summary: the main aim of this research is to ascertain whether ketamine would be a more effective anaesthetic for electroconvulsive therapy (ect) than the standard anaesthetic. in doing so the investigators aim to examine the effect of ketamine on ratings of depressive symptoms, the number of required ect treatments, and the effect of this anaesthetic on memory.

according to who statistics, depression is amongst the leading causes of disability worldwide. in its more severe forms, it can be life threatening. the most severe forms of depression, or those that fail to respond to chemical treatment are treated with electroconvulsive therapy (ect). the treatment is highly effective, and undoubtedly saves lives, but a range of factors, including side effect profile, the necessity for extended hospital care, and stigma, restricts its use. a recent study has shown that patients who receive ketamine as the anaesthetic for ect experience an earlier reduction in depressive symptoms and have a greater reduction in depressive symptoms than those receiving propofol (okamoto et al., 2009). however, in this study eight ect treatments were given to all participants so it is unknown whether ketamine could have reduced the number of treatments required. overall, these studies suggest that as well as being a neuroprotective agent; ketamine may also have an antidepressant effect. given these findings it is hypothesized that the use of ketamine in ect treatment may reduce the number of ect sessions required due to this drug's effects on depression ratings. our main research question is whether the use of ketamine as the anaesthetic for ect treatment for depression improves the treatment outcome with respect to speed of response and reduction in side effects when compared to conventional anaesthesia.

Eligibility criteria:
inclusion criteria: * between the ages of 18 and 65 years old * diagnosed with depression and being referred for ect * american society of anesthesiologists (asa) score of 1 or 2 * patient receiving ect on an informal basis (i.e. consenting to treatment and able to give informed consent) exclusion criteria: * pre-existing neurological disease or cognitive impairment * co-morbid psychiatric diagnoses * pre-existing hypertension * severe respiratory tract disease * major cardiovascular disease * pacemakers * cerebrovascular disorder or malformation * intracranial mass lesions * seizure disorder * intracranial electrode or clips * intra-ocular pathology * endocrine or metabolic disease * severe hematologic disease * severe fracture * not able to give consent * pregnancy

Keywords: depression electroconvulsive therapy ketamine
the addition of hydromorphone to local anesthetics for the repair of inguinal hernias in elderly patients

Conditions: Inguinal Hernia

Summary: to compare the clinical and postoperative analgesic effects of hydromorphone combined with ropivacaine and ropivacaine alone in quadrangular muscle block for open inguinal hernia in elderly patients.

elderly patients selected for lichtenstein hernia repair in our hospital who met the inclusion and exclusion criteria and obtained informed consent were included in this trial, and were randomly divided into experimental group by random number table method: 0.375% ropivacaine combined with hydromorphone block group, and control group: 0.375% ropivacaine block group alone.

Eligibility criteria:
inclusion criteria: * age 60 and above. * admission to hospital for open inguinal hernia surgery is consistent with the -indications of this surgical modality, asa grades 1 to 3. * no recent use of sedatives, opioids, or other analgesics. * good compliance, signed informed consent. * complete clinical data. exclusion criteria: * there are serious cardiovascular and cerebrovascular diseases. * abdominal infection. * coagulation dysfunction or receiving anticoagulation therapy. * local anesthesia drug allergy. * can not cooperate with the corresponding operation, suffering from mental illness. * previous surgical history of the corresponding position in the abdomen that may interfere with the surgical process of this study.

Keywords: hydromorphone quadratus lumbois block old people
a phase 2 study to evaluate safety and efficacy of amb-05x in subjects with idiopathic pulmonary fibrosis

Conditions: IPF

Summary: amb-053-01 is a randomized, placebo controlled, multicenter study which will enroll approximately 36 subjects ages 40 and older with ipf for 6 doses over a 24-week dosing period.


Eligibility criteria:
inclusion criteria: 1. subjects ≥40 years old. 2. history of confirmed diagnosis of ipf 3. chest hrct at screening 4. subjects who are either: * not being treated with approved ipf therapies (i.e., nintedanib or pirfenidone) or * being treated with approved ipf therapies (i.e., nintedanib or pirfenidone) 5. has fvc ≥45% predicted of normal and dlco ≥25% and ≤90% predicted 6. has a fev1/fvc ratio (tiffeneau-pinelli index) ≥ 0.70 7. has adequate hematologic, hepatic, and renal function exclusion criteria: 1. prior investigational drug use within 30 days or 5 half-lives 2. presence of emphysema exceeding the extent of fibrosis 3. active or anticipated need for lung transplant 4. treatment with prednisone 5. active cancer 6. active or chronic infection with hcv, hbv, or hiv 7. known active tuberculosis 8. history of or current immunosuppressive condition 9. ipf exacerbation within 12 weeks 10. lower respiratory-tract infection requiring antibiotic therapy 11. smoking 12. other forms of interstitial lung disease 13. history of lung volume reduction surgery or lung transplant 14. contraindications for forced expiratory maneuvers during spirometry 15. unstable cardiac or pulmonary disease (other than ipf) 16. fridericia-corrected qt interval (qtcf) ≥ 450 ms (men) or ≥ 470 ms (women) 17. history of drug or alcohol abuse -

Keywords: idiopathic pulmonary fibrosis ipf
feasibility of virtual reality in children with neuromuscular disease, effectiveness of virtual reality and biofeedback

Conditions: Neuromuscular Disease; Duchenne Muscular Dystrophy; Spinal Muscular Atrophy; Virtual Reality; Biofeedback

Summary: our study is a randomized controlled study and the subjects included in the study will be divided into three groups as virtual reality training, biofeedback training, and conventional rehabilitation.

we have 3 purposes: 1. determine the feasibility of virtual reality training in children with neuromuscular disease. 2. to determine the effect of virtual reality, biofeedback training, and conventional rehabilitation on functional levels and balances of children with neuromuscular disease. 3. to compare the motivation of children with neuromuscular disease to virtual reality, biofeedback training, and conventional rehabilitation.

Eligibility criteria:
inclusion criteria: * volunteer to participate in the study * being diagnosed with the neuromuscular disease * no other systemic or neurological disease * no significant visual or auditory loss * continuation of ambulation (10 m walking independently) * be able to understand simple commands exclusion criteria: * performing a drug change at 3 months before treatment or during treatment which may affect muscle strength * acute inflammation in the musculoskeletal system * finding any orthopedic problem that prevents activities during the research

Keywords: motivation neuromuscular disease duchenne muscular dystrophy spinal muscular atrophy virtual reality biofeedback training